Western Sky Medical Research

(El Paso Institute for Medical Research and Development)
Lyndon E. Mansfield, MD
Director
2121 Wyoming Ave.
El Paso, Texas 79903
(915) 544-2557

List of Research Studies

279. **Mylan (DEY Pharma, L.P.) Protocol: 201-085**
A randomized, double-blind, placebo-controlled study to evaluate the safety of long-term use of Perforomist (formoterol fumarate) inhalation solution in subjects with chronic obstructive pulmonary disease (COPD).
Ongoing

278. **Teva Pharmaceuticals Protocol: BDB-AS-304**
A randomized, double-blind, placebo-controlled, parallel-group, 12-week clinical study to assess the efficacy and safety of Beclomethasone Dipropionate (80 and 160 mcg/day) delivered via breath-actuated inhaler (BAI) in adolescent and adult patients 12 years of age and older with persistent asthma.
Ongoing

277. **Teva Pharmaceuticals Protocol: BDB-AS-301**
A randomized, double-blind, double-dummy, placebo-controlled, parallel-group, 12-week clinical study to assess the efficacy and safety of 320 or 640 mcg/day of Beclomethasone Dipropionate delivered via breath-actuated inhaler (BAI) or metered-dose inhaler (MDI) in adolescent and adult patients 12 years of age and older with persistent asthma.
Ongoing

276. **Teva Pharmaceuticals Protocol: BDP-AR-306**
A randomized, double-blind, placebo-controlled, parallel-group, 12-Week, clinical study designed to assess the efficacy and safety of BDP Nasal Aerosol (80 mcg, once daily) in pediatric subjects (4 to 11 years of age) with Perennial allergic rhinitis (PAR).
Completed: December 11, 2013

275. **Sanofi-Aventis Protocol: DRI 12544**
A randomized, double-blind, placebo-controlled, dose-ranging study to evaluate dupilumab in patients with moderate to severe, uncontrolled asthma.
Ongoing

274. **Pearl Therapeutics Inc. Protocol: PT003006**
A randomized, double-blind (test products and placebo), chronic dosing (24 weeks), placebo-controlled, parallel-group, multi-center study to assess the efficacy and safety of PT003, PT005 and PT001 in subjects with moderate to very severe COPD, compared with placebo and SpirivaHandihaler(Tiotropium Bromide 18 mcg, open-label) as an active control.
Ongoing

273. **Novartis Pharmaceuticals Inc. Protocol: CIGE025B US28**
Long-term natural history of patients with severe or difficult-to-treat asthma from the TENOR observational study.
Ongoing

272. **Novartis Pharmaceuticals Inc. Protocol: CQVA149A2210**

A multi-center, randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy, safety and tolerability of five different doses of inhaled indacterol (QAB149) delivered via the single dose dry powder inhaler (SDDPI) in patients with persistent asthma.
Ongoing

271. **Mylan Protocol: MOMT-12084**
A randomized, double-blind, multiple-dose trial of Mometasone Nasal Spray, 50 mcg (Mylan), NasonexNasal Spray, 50 mcg (MSD-US, NasonexNasal Spray Suspension, 50 mcg (MSD-EU) and placebo for the treatment of the signs and symptoms of seasonal allergic rhinitis in 1520 male and female volunteers.
Pending Close Out

270. **Genentech Protocol: GB28689 (La Volta) Phase 3**
A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of Lebrikizumab in patients with uncontrolled asthma who are on inhaled corticosteroids and a second controller medication.
Ongoing

269. **Boehringer Ingelheim Protocol: 1012.67**
A comparison of Ipratropium Bromide and Albuterol Inhalation Spray delivered via the Respimat Inhaler with Albuterol Sulfate HFA inhalation Aerosol and ipratropium bromide HFA inhalation aerosol in a 4 week (28 day), multi-center, double-blind, double-dummy, three-way, cross-over study following chronic q.i.d. administration in patients with chronic obstructive pulmonary disease.
Pending start up

268. **Amphastar Pharmaceuticals Inc. Protocol: API-E004-CL-D2**
Evaluation of Efficacy and Safety for Single Dose E004 in Children with Asthma
Completed: September 24, 2013

267. **Amgen Inc. Protocol: 20120141**
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Inadequately Controlled Asthma and High Bronchodilator Reversibility.
Ongoing

266. **Novartis Pharmaceuticals Protocol: CQVA149A2336**
A 12-week treatment, multi-center, randomized double-blind, parallel-group, placebo and active controlled study to assess the efficacy, safety, and tolerability of QVA149 (indacaterol maleate/glycopyrronium bromide) in COPD patients with moderate to severe airflow limitation.
Ongoing

265. **Teva Protocol: FpS-AS-202**
A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax (Fluticasone Propionate Inhalation Powder) Administered Twice Daily compared with Placebo in Adolescent and Adult Subjects with Severe Persistent Asthma Uncontrolled on High dose Inhaled Corticosteroid Theapy.
CRO/Sponsor: PPD
Completed: December 2013

264. **Teva Protocol: FSS-AS-201**
A Six-Period Crossover, Dose-Ranging Study to Evaluate the Efficacy and Safety of Four Doses of FS Spiromax(Fluticasone Propionate/Salmeterol Xinafoate Inhalation Powder) Administered as Single Doses Compatred with Single Doses of Fluticasone Propionate Spiromax and Open Label Advair Diskus in Adult and Adolescent Subjects with Persistent Asthma
CRO/Sponsor: RPS, Inc
Completed: July 18, 2013

263. **Cephalon Protocol: C38072/3085**
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of reslizumab (3.0 mg/kg) as Treatment for Patients with Eosinophilic Asthma WhoCompleted a Prior Cephalon-Sponsored Study in Eosinophilic Asthma.
CRO/Sponsor: PPD
Ongoing

262. **GlaxoSmithKline Protocol: HZA116863**
A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/ Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder in the Treatment of persistent

Asthma in Adults and Adolescents.
CRO/Sponsor: GSK
Completed: November 20, 2013

261. **Teva Protocol: ABS-AS-307**
A multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax in Subjects with asthma.
CRO/Sponsor: RPS, Inc.
Pending Close out

260. **Novartis Protocol: CNVA237A2319**
A multi-center, randomized, double-blind, 52-week study to assess the safety of NVA237 compared to QAB149 in patients with Chronic Obstructive Pulmonary Disease (COPD) who have moderate to severe airflow limitation.
CRO/Sponsor: Novartis
Ongoing

259. **Boehringer Ingelheim Protocol: 122252**
A randomized, double-blind, parallel group study to assess the efficacy and safety of 12 weeks of once daily, orally inhaled, co-administration of olodaterol 5 mcg (delivered by the Respimat Inhaler) and tiotropium 18 mcg (delivered by the HandiHaler) compared to once daily, orally inhaled, co-adminsitration of placebo (delivered by the HandiHaler) in patients with Chronic Obstructive Pulmonary Disease (COPD)
CRO/Sponsor: Boeheringer Ingelheim
Completed: January 9, 2014

258. **Astra Zeneca Protocol: D589GC00001 (Chase I)**
A Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 mcg bid with placebo: a 6-week efficacy and safety study in children aged 6 to <12 years with asthma.
CRO/Sponsor: Quintiles, Inc.
Completed: August 14, 2013

257. **Rigel Pharmaceuticals, Inc. Protocol: C-940343-004**
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Doses of Inhaled R940343 in Patients with Mild to Moderate Allergic Asthma.
CRO/Sponsor: Rigel Pharmaceuticals, Inc.
Completed: September 16, 2013

256. **Forest Research Institute Protocol: LAC-MD-21**
Phase II, Randomized, Placebo-controlled, Double-blind, Double-dummy, 5-period Complete Crossover study of the Bronchodilator Effects of Formoterol Fumarate Inhalation Powder in Patients with Mild to Moderate Asthma.
CRO/Sponsor: Forest Research Institute
Completed: May 8, 2013

255. **Genentech (Roche) Protocol: GB 27980**
A Phase IIB, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Dosing Regimens of MEMP1972A in Adults with Allergic Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids and a Second Controller (COSTA).
CRO/Sponsor: Covance
Completed: November 6, 2012

254. **Boehriger Ingelheim Protocol: 205.445**
A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (25 µg and 5 µg) delivered via Respimatinhaler once daily in the evening over 48 weeks in children (6 to 11 years old) with moderate persistent asthma.
CRO/Sponsor: Boehriger Ingelheim
Ongoing

253. **Boehringer Ingelheim Protocol: 205.444**
A phase III, randomised, double blind, placebo-controlled, parallel group study to assess the efficacy and safety over 48 weeks of orally inhaled Tiotropium bromide (2.5 µg and 5 µg once daily) delivered by the Respimatinhaler in adolescents (12 to 17 years old) with moderate persistent asthma.
CRO/Sponsor: Boehringer Ingelheim
Completed: May 13, 2013

252. **Array BioPharma Protocol: 502-201**
A Phase 2 Randomized, Double-Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Arry-502 in Adults with Persistent Asthma
CRO/Sponsor: Array BioPharma
Completed: July 17, 2013

251. **Genentech (F. Hoffmann-La Roche, Ltd.) Protocol: GB27864**
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Uncontrolled Asthma Who Are On Inhaled Corticosteroids and a Second Controller Medication
CRO/Sponsor: Covance
Completed: November 6, 2013

250. **Forest Research Institute, Inc Protocol: LAC-MD-36**
A Phase III, Long-Term, Randomized, Double-Blind, Extension Study of the Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients with Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
CRO/Sponsor: Forest Research Institute, Inc
Completed: August 5, 2013

249. **Sunovion Pharmaceutical Inc, Protocol: 060-305**
A 2-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6 to 11 Years with Seasonal Allergic Rhinitis.
CRO/Sponsor: Sunovion Pharmaceutical Inc.
Completed: May 16, 2013

248. **Merck (Schering-Plough Research Institute) Protocol: P06241/P202**
A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults with Persistent Asthma.
CRO/Sponsor: Covance
Ongoing

247. **Sunovion Pharmaceuticals, Inc Protocol: 060-306**
A 12-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjeects 6-11 Years with Perennial Allergic Rhinitis.
CRO/Sponsor: Sunovion Pharmaceuticals, Inc
Completed: March 21, 2013

246. **Amphastar Pharmaceuticals, Inc. Protocol: API-E004-CL-C2**
A 3-Month Safety Evaluation Extension to the 12-Week E004-C Study In Asthma Patients (A double Blinded, Placebo-Controlled, Parallel, 3-Month Safety Study in Adolescent and Adult Patients with Asthma.
CRO/Sponsor: Amphastar Pharmaceuticals, Inc
Completed: October 31, 2013

245. **GlaxoSmithKline Protocol: FFA115285**
A randomized, double-blind, double-dummy, placebo controlled multi-centre study to evaluate the efficacy and safety of fluticasone Furoate inhalation powder and fluticasone propionate inhalation powder in the treatment of asthma in adults and adolescents not currently treated with inhaled corticosteroids.
CRO/Sponsor: GSK
Completed: October 18, 2012

244. **Amphastar Pharmaceuticals, Inc. Protocol: API-E004-CL-D**
Epinephrine Inhalation Aerosol USP, An HFA-MDI (E004): Clinical Study-D for Evaluation of Efficacy and Safety of E004 in Children with Asthma (A Randomized, Double-Blind, Placebo-Controlled, Two Arm, Parallel, 4-Week Study in 4-11 years old Children with Asthma)
CRO/Sponsor: Amphastar Pharmaceuticals, Inc
Completed: October 30, 2012

243. **GlaxoSmithKline Protocol: HZA106847**
A Randomized, Double-Blind, Double-Dummy, Crossover Comparison of Fluticasone Furoate/Vilanterol 100/25

mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Asthmatic Adolescents and Adult Subjects with Exercise-Induced Bronchoconstriction.
CRO/Sponsor: GSK
Cancelled

242. **Sunovion Pharmaceuticals Inc. Protocol: SEP060-308**
A 6-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subject 6-11 Years with Perennial Allergic Rhinitis.
CRO/Sponsor: PPD
Completed: January 10, 2012

241. **Sunovion Pharmaceuticals Inc Protocol: SEP060-302**
A Randomized Two Period Two-Way Crossover Study to Evaluate Patients Preference, Statisfaction and Efficacy of a Nasal Aerosol Versus an Aqueous Nasal Spray Used for the Treatment of Allergic Rhinitis.
CRO/Sponsor: PPD
Completed: December 14, 2011

240. **Forest Research Institute Protocol: LAC-MD-32**
A Long-Term, Randomized, Study of the Safety and Tolerability of a Fixed-Dose Combination of Aclidinium Bromide/Formoterol compared with Formoterol Fumarate in Patients with Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD),
CRO/Sponsor: Forest Research Institute
Completed: May 7, 2013

239. **Forest Research Institute Protocol: LAC-MD-31**
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluation the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo for 24-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD).
CRO/Sponsor: Forest Research Institute.
Completed: May 6, 2013

238. **Cephalon Inc. Protocol C38072/3083**
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma.
CRO/Sponsor: PPD
Pending Close Out

237. **Amphastar Pharmaceuticals, Inc. Protocol: API-E004-CL-C**
A randomized, double-and evaluator-blinded, active-and placebo-controlled, three-arm, parallel, 12-week study in adolescents and adult patients with asthma.
CRO/Sponsor: Amphastar
Completed: September 2012

236. **Boehringer Ingelheim Protocol: 1268.16**
Randomised, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 6 weeks of oral BI671800 ED 400 mg b.i.d., Montelukast 10 mg q.d., or placebo in symptomatic asthma patients on Fluticasone propionate MDI.
CRO/Sponsor: Boehringer Ingelheim
Completed: September 2011

235. **Sanofi-Aventis U.S. Inc., Protocol: ACT11457**
A randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy, safety, and tolerability of SAR231893/REGN668 administered subcutaneously (SC) once weekly for 12 weeks in patients with persistent moderate to severe eosinophilic asthma who are partially controlled/uncontrolled by inhaled corticosteroids (ICS) plus long-acting Beta 2 agonist (LABA) therapy.
CRO/Sponsor: Sanofi-Aventis
Completed: September 2012

234. **Amgen, Inc. Protocol: 20090203**

A randomized, double-blind, placebo-controlled phase 2 study to determine the safety and efficacy of AMG 827 in subjects with inadequately controlled asthma.
CRO/Sponsor: Amgen
Completed: April 2012

233. **Amgen, Inc. Protocol: 20080615**
A randomized, double-blind, placebo-controlled, multiple dose phase 2 study to determine the safety and efficacy of AMG 853 in subjects with inadequately controlled asthma.
CRO/Sponsor: Amgen
Completed: April 2011

232. **Alcon Protocol: C-08-32**
Safety of PatanaseNasal Spray in Patients with Perennial Allergic Rhinitis
CRO/Sponsor: Alcon
Completed: January 2011

231. **Boehringer Ingelheim Protocol: 1268.17**
A randomized, double-blind, placebo and active controlled, parallel group study to evaluate the safety and efficacy of 6-week treatment with oral doses of 50 mg b.i.d., 200 mg b.i.d., BI 671800 ED in steroid-naive patients with persistent asthma.
CRO/Sponsor: Boehringer Ingelheim
Completed: Aug. 2011

230. **Actelion Protocol: AC-060A202**
A multi-center, double-blind, placebo-controlled, parallel-group study to establish proof-of-concept and explore the efficacy of different doses of ACT-129968 in adult patients with partly controlled asthma.
CRO/Sponsor: Actelion
Completed: April 2012

229. **Boehringer Ingelheim Protocol: 205.419**
A phase 3 randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimatinhaler (2.5 and 5 mcg once daily) compared with placebo and salmeterol HFA MDI (50 mcg twice daily) over 24 weeks in patients with moderate persistent asthma.
CRO/Sponsor: Boehringer Ingelheim
Completed: January 24, 2013

228. **Boehringer Ingelheim Protocol: 205.416**
A phase 3 randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimatinhaler (5mcg-day) over 48 weeks as add-on controller therapy on top of usual care in patients with severe persistent asthma.
CRO/Sponsor: Boehringer Ingelheim
Completed: on September 2011

227. **Sepracor Protocol: 060-635**
A 6-month open-label, long-term safety extension study of once daily Ciclesonide HFA Nasal Aerosol (160 mcg) in the treatment of perennial allergic rhinitis (PAR) in subjects 12 years and older.
CRO/Sponsor: Sepracor
Completed: January 2011

226. **Sepracor Protocol: 060-633**
A 6-month randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of once daily Ciclesonide HFA nasal aerosol (80 and 160 mcg) in the treatment of perennial allergic rhinitis (PAR) in subjects 12 years or older.
CRO/Sponsor: Sepracor
Completed: July 2010

225. **GlaxoSmithKline Protocol: HZA106839**
Study administration information for a randomized, double-blind, double-dummy, active comparator, parallel group, multicenter study to evaluate the safety of once-daily Fluticasone Furoate/GW642444 Inhalation powder for 52 weeks in adolescents and adult subjects with Asthma.
CRO/Sponsor: GSK
Completed: February 2011

224. **Teva Branded Pharmaceuticals Protocol: BDP-AR-303**
A randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical study to assess the long-term efficacy and safety of BDP HFA Nasal Aerosol (320 mcg, once daily) in adults and adolescent subjects (12 years and older) with perennial allergic rhinitis (PAR). Teva
Completed: April 2011

223. **Teva Branded Pharmaceuticals Protocol: ABS-AS-306**
A multi-center 52-week study to assess the safety of Albuterol Spiromaxin subjects with Asthma.
CRO/Sponsor: Teva
Completed: April 2011

222. **Teva Branded Pharmaceuticals Protocol: BDP-AR-305**
A randomized, double-blind, placebo-controlled, parallel-group, multi-center, dose finding study to assess the efficacy and safety of BDP HFA Nasal Aerosol in pediatric subjects (6 to 11 years of age) with seasonal allergic rhinitis (SAR)
CRO/Sponsor: Teva
Completed: Aug 2011

221. **Meda Pharmaceuticals Protocol: MP411**
Randomized, double-blind, placebo-controlled trial of the safety an d efficacy of MP03-36 (0.15%solution) and MP03-33 (0.10% solution) in children ages =6 to <12 with Perennial Allergic Rhinitis.
Completed: June 2011

220. **Genentech Inc. Protocol: Q4882g**
A phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, response duration and safety of Xolair (omalizumab) in patients with chronic idiopathic urticaria (CIU) who remain symptomatic despite antihistamine treatment (H1).
CRO/Sponsor: Quintiles
Completed: September 27, 2012

219. **Novartis Protocol: CQAB149B2355**
A 12-week treatment, multi-center, randomized, double-blind, placebo-controlled, parallel- group study to assess the efficacy and safety of once daily indacaterol in patients with chronic obstructive pulmonary disease.
CRO/Sponsor: Novartis
Completed: August 2010

218. **Novartis Protocol: CQAB149B2357**
A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to assess the efficacy and safety of different doses of indacaterol in adult patients with persistent asthma, using salmeterol as an active control.
CRO/Sponsor: Novartis
Completed: July 2010

217. **Boehringer Ingelheim Protocol: 126853**
A randomized, double-blind, placebo-controlled, efficacy and safety cross-over study of 4 weeks of oral BI 671800 ED 200 mg twice daily or 400 mg once daily administered in the morning (AM) or evening (PM), in symptomatic asthma patients on inhaled Fluticasone propionate MDI. Boehringer Ingelheim
Completed: May 2011

216. **MedImmune Protocol: MI-CP-198**
A Phase 2b, Randomized study to evaluate the efficacy and safety of subcutaneous MEDI-528 in adults with uncontrolled asthma.
CRO/Sponsor: MedImmune
Completed: March 20, 2012

215. **Biota Protocol: BTA798-202**
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of BTA798 in Asthmatic Adults with Symptomatic Human Rhinovirus Infection.
CRO/Sponsor: i3 Research
Completed: April 2011

214. **AstraZeneca Protocol: D589GC00002 (Chase 2)**
A Phase 2, randomized, blinded, 5-period, cross-over, placebo and active-controlled, multicentered, dose-finding

study comparing single doses of formoterol 2.25 mcg, 4.5 mcg, And 9 mcg delivered via Symbicort pMDI and Foradil 12 mcg evaluating the relative bronchodilating effects and safety in children with asthma who are receiving background treatment with Budesonide pMDI 160 mcg bid.
CRO/Sponsor: Quintiles
Completed: March 21, 2012

213. **Forest Research Institute, Inc. Protocol: LAS-MD-35**
A Long-Term, Randomized, Double-Blind Study of the Safety, Tolerability and Efficacy of Aclidinium Bromide At Two Dosage Levels When Administered to Patients with Moderate To Severe, Stable Chronic Obstructive Pulmonary Disease
CRO/Sponsor: Forest
Completed: June 2011

212. **Forest Research Institute Protocol A2-8432**
Semi-structured interviews to explore patient perspectives of PDE4 treatment for COPD.
CRO/Sponsor: UBC
Completed: 2009

211. **Novartis Pharmaceutical Corporation Protocol: CNVA237A2303**
A 52-week treatment, randomized, double-blind, placebo controlled, with open label Tiotropium, parallel-group study to assess the efficacy, safety and tolerability of NVA237 in patients with chronic obstructive pulmonary disease.
CRO/Sponsor: PPD
Completed: August 2011

210. **Sepracor Protocol: 051-359**
A safety, efficacy, and tolerability study of daily dosing with levalbuterol tartrate HFA MDI and placebo in subjects aged birth to <48 months with asthma.
CRO/Sponsor: Omnicare Clinical Research
Completed: August 16, 2011

209. **Allergan Protocol: 192371-016-00**
A multicenter, randomized, double-masked, parallel-group study evaluating the Efficacy and safety of cyclosporine ophthalmic solution 0.010% compared with its Vehicle administered QID for 3 months followed by a 9-month open-label phase in patients With atopic keratoconjunctivitis.
CRO/Sponsor: Allergan
Completed: 2010

208. **Novartis Pharmaceutical Corporation Protocol: CQAB149B2341**
A randomized, double-blind, controlled, parallel group, 12-week treatment study to Compare the efficacy and safety of the combination of indacaterol 150 mcg once daily With open label tiotropium 18 mcg once daily in patients with moderate to severe Chronic obstructive pulmonary disease.
CRO/Sponsor: Novartis Pharmaceutical Corporation
Completed: 2009

207. **Western Sky Medical Research Protocol: WSMR 2008-2**
A comparison of the bronchodilating activity of Symbicort pMDI 160/4.5 used in the Conventional manner and with a valved, spacer holding chamber (Aerochamber Plus)
CRO/Sponsor: Astra Zeneca
Completed: 2009

206. **Boehringer Ingelheim Pharmaceuticals, Inc. Protocol: 1012.57**
A multicenter, randomized study starting with a 4-week, 2-way crossover double-blind Treatment phase comparing th3e efficacy and safety of CombiventCFC MDI to albuterol HFA MDI followed by a 4-week open-label Combivent Respimattreatment phase when All study drugs are used for symptom relief 'as needed' in patients with moderate-to- Severe asthma.
CRO/Sponsor: Boehringer Ingelheim
Completed: 2009

205. **Novartis Pharmaceutical Corporation Protocol: CQAB149B2349**
A 12 week treatment, multi-center, randomized, parallel group, double blind, double Dummy study to assess the superiority of indacaterol (150 mcg o.d.) via SDDPI in Patients with moderate to severe COPD, using salmeterol

(50 mcg b.i.d.) as an active Comparator delivered via a DISKUS inhaler
CRO/Sponsor: Novartis Pharmaceutical Corporation
Completed: 2009

204. **Sanofi-Aventis US Protocol: XRG5029C/3503**
A randomized, multicenter, double-blind, placebo-controlled, parallel group study of the 12 month effect of treatment with once daily triamcinolone acetonide (NASACORTAQ Nasal Spray 110 mcg) on the growth velocity of children, 3 to 9 years of age, with perennial Allergic rhinitis.
CRO/Sponsor: MDS Pharma
Completed: May 2011

203. **Novartis Pharmaceutical Corporation Protocol: CIGE025AUS33**
A 26-week randomized, double-blind, placebo-controlled, multi-center study to evaluate the Effect of omalizumab on markers of asthma impairment in patients with persistent allergic Asthma.
CRO/Sponsor: Novartis Pharmaceutical Corporation
Completed: 2009

202. **Novartis Pharmaceutical Corporation Protocol: CLAF237B2224**
A multi-center, randomized, double-blind study to evaluate the efficacy and long-term Safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients With type 2 diabetes.
CRO/Sponsor: Novartis Pharmaceutical Corporation
Completed: 2009

201. **Novartis Pharmaceutical Corporation Protocol: CSPV100AUS01**
An 8 week randomized, double-blind, parallel group, multi-center, active controlled study to Evaluate the efficacy and safety of Valsartan administered in combination with Aliskiren (160/150 mg, 320/300 mg) versus Valsartan alone (160 mg, 320 mg) in patients with Stage 2 hypertension.
CRO/Sponsor: Novartis Pharmaceutical Corporation
Completed: 2009

200. **Novartis Pharmaceutical Corporation Protocol: CLAF237B2201**
A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as monotherapy in patients with type 2 diabetes.
CRO/Sponsor: Novartis Pharmaceutical Corporation
Completed: 2009

199. **Phenomix Corporation Protocol: PHX1149-PROT300E**
An open label, multi-center, long-term extension study to evaluate the safety of Dutogliptin PHX1149T in subjects with type 2 diabetes mellitus. MDS Pharma Services
Completed: July 2010

198. **Phenomix Corporation Protocol: PHX1149-PROT301**
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of Dutogliptin/PHX1149T as Monotherapy in Subjects with Type 2 Diabetes Mellitus
CRO/Sponsor: MDS Pharma Services
Completed: 2009

197. **Novartis Pharmaceutical Protocol: CVAH631BUS08**
A 16 week multi-center, randomized, double-blind study to evaluate efficacy and safety of Valsartan/hydrochlorothiazide (HCTZ) combination therapy compared to patients initiated With valsartan monotherapy or hydrochlorothiazide monotherapy in very elderly patients With essential hypertension.
CRO/Sponsor: Premier Research
Completed: 2009

196. **Forest Research Institute Protocol: GRC-MD-50**
Dose-Ranging Study of the Efficacy and Safety of Oglemilast in Patients with Chronic Obstructive Pulmonary Disease
CRO/Sponsor: Forest Research Institute
Completed: 2009

195. **GlaxoSmithKline Protocol: FFR110537**
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolescents 12 Years of Age

and Older with Perennial Allergic Rhinitis
CRO/Sponsor: GlaxoSmithKline
Completed: February 2011

194. **SkyePharma Protocol: SKY2028-1-003**
A Randomized, Double-blind, Placebo-and Active-Controlled, Parallel Group, 6-week Study to Evaluate the Effect of Multiple Doses of FlutiForm 250-10 ug HFA pMDI twice daily, FlutiForm 100/10 ug HFA pMDI twice daily, Prednisone and Placebo on the Hypothalamic- Pituitary-Adrenal Axis in Adult Subjects with Mild to Moderate Asthma
CRO/Sponsor: Abbott
Completed: October 2008

193. **Novartis Protocol: CQAB149B2335SE**
A 26-week extension to a 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to assess safety, tolerability and efficacy of two doses of indacaterol (150 and 300 ug o.d.) in patients with chronic obstructive pulmonary disease
CRO/Sponsor: Novartis
Completed: March 2009

192. **Ception Protocol: RES-5-0010**
An Efficacy and Safety Study of Reslizumab (CTX55700) in the Treatment of Poorly Controlled Asthma in Subjects with Eosinophilic Airway Inflammation
CRO/Sponsor: Premier Research
Completed: December 2008

191. **UCB: Protocol RPCE07K2412 (A00430)**
A multi-center, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and impact on health-related quality of life of levocetirizine 5 mg once daily given for 2 weeks in subjects 18 years of age and older with seasonal allergic rhinitis.
CRO/Sponsor: Clinsys
Completed: August 2008

190. **AstraZeneca: Protocol D525BC00007**
A 2 x 1-week, cross-over, multicenter, randomized trial to evaluate the functionality Of and electronic nebulizer (eFlow for use by parents/caregivers on asthmatic or Wheezing children
CRO/Sponsor: Omnicare
Completed: August 2008

189. **GlaxoSmithKline Protocol: FFR101782**
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110 mcg QD on Growth in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis
CRO/Sponsor: GlaxoSmithKline
Completed: February 2011

188. **Novartis Protocol: CQAB149B2346**
A 12-week treatment, multi-center, randomized, double-blind, placebo controlled, parallel group study to assess the efficacy and safety of Indacaterol (150 mg o.d.) in patients with chronic obstructive pulmonary disease.
CRO/Sponsor: Novartis
Completed: September 2008

187. **Novartis Protocol: CQAB149B2335S**
A 26-week treatment, multicenter, randomized, double-blind, double dummy, placebo- controlled, adaptive, seamless, parallel-group study to assess the efficacy, safety and tolerability of two doses of Indacaterol (selected from 75, 150, 300 & 600 ug o.d.) in patients with chronic obstructive pulmonary disease using blinded Formoterol 912ug b.i.d) and open label Tiotropium (18 ug o.d.) as active controls.
CRO/Sponsor: Novartis
Completed: September 2008

186. **GlaxoSmithKline: Protocol ADA109057**
A Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects

with Asthma
CRO/Sponsor: GlaxoSmithKline
Completed: March 2009

185. **GlaxoSmithKline: Protocol FFU105924**
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110 mcg Fluticasone Furoate Nasal Spray and 200 mcg Fluticasone Propionate Nasal Spray in Adults Subjects With Seasonal Allergic Rhinitis
CRO/Sponsor: GlaxoSmithKline
Completed: November 2007

184. **Med Pointe Pharmaceuticals: Protocol MP436**
Active-Controlled Trial of the Safety and Tolerability of MP03-36 in Patients with Perennial Allergic Rhinitis
CRO/Sponsor: i3 Research
Completed: September 2008

183. **Schering Plough Research Institute: Protocol P04073**
A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/ Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate And Formoterol Monotherapy in Subjects with Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids
CRO/Sponsor: Quintiles
Completed: November 2008

182. **Schering Plough Research Institute: Protocol P04334**
A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate And Formoterol Monotherapy in Subjects with Persistent Asthma Previously Treated With Medium-Dose Inhaled Glucocorticosteroids
CRO/Sponsor: Quintiles
Completed: November 2008

181. **Med Pointe Pharmaceuticals: Protocol MP439**
Randomized, double-blind, placebo-controlled trial of the safety and efficacy of MP03-36 In patients with seasonal allergic rhinitis.
CRO/Sponsor: Omnicare
Completed: January 2008

180. **Critical Therapeutics, Inc.: Protocol CTI-04-C07-202**
Assessment of pulmonary function, safety, tolerability, and pharmacokinetics (PK) of Zileuton injection in patients with chronic stable asthma.
CRO/Sponsor: Clinquest
Completed: May 2008

179. **Critical Therapeutics, Inc.: Protocol CTI-03-C07-401**
A randomized, double-blind, placebo-controlled study to evaluate the efficacy of Zileuton Controlled-Release (CR) tablets versus placebo in adult patients with asthma poorly Controlled on moderate dose inhaled corticosteroids (ICS).
CRO/Sponsor: Clinquest
Completed: July 2008

178. **Amgen, Inc.: Protocol 20060161**
A randomized, double-blind, placebo-controlled, multiple dose phase 2 study to determine The safety and efficacy of AMG 317 in subjects with moderate to severe asthma.
CRO/Sponsor: RPS
Completed: December 2008

177. **Astra Zeneca: Protocol D5896C00025**
A two-week, randomized, double-blind study assessing the onset of effect questionnaire (OEQ) administered pre-dose versus post-dose in adult subjects (= 18 years of age) with mild to moderate asthma, receiving SYMBICORTpMDI 80/4.5 mcg x 2 actuations twice daily or Budesonide HFA pMDI 80 mcg x 2 actuations twice daily.
CRO/Sponsor: Parexel

Completed: February 2008

176. **Eli Lilly and Company Protocol: H7U-MC-IDAS**
A Pivotal, Open-Label, Parallel Study to Evaluate the Safety and Efficacy of Human Insulin Inhalation Powder (HIIP) Compared to Injectable Insulin in Patients with Diabetes and COPD or Asthma
CRO/Sponsor: Quintiles
Completed: November 2007

175. **Merck & Co., Inc Protocol: 301-02**
A Multicenter, Randomized, Double-Blind Study Comparing the Clinical Effects of Intravenous Montelukast with Placebo in Pediatric Patients (ages 6 to 14 years) with Acute Asthma
CRO/Sponsor: PRA International
Completed: July 2007

174. **GlaxoSmithKline Protocol: ADA103575**
A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200 mcg QD versus Montelukast 10 mg QD in Adolescents and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving ADVAIR DISKUS00/50 mcg BID or Placebo BID
CRO/Sponsor: GlaxoSmithKline
Completed: February 2007

173. **Novartis Protocol: CLMF237A2302**
A randomized, double-blind, controlled, multicenter study to compare the effect of 24 weeks treatment with a fixed combination therapy of vildagliptin and metformin to the individual monotherapy components in drug-naive patients with Type 2 Diabetes
CRO/Sponsor: Novartis
Completed: July 2008

172. **Novartis Protocol: CVEA489A2302**
An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertension.
CRO/Sponsor: Novartis
Completed: October 2007

171. **MedPointe Protocol: MP435**
A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03- 36 in Patients with Perennial Allergic Rhinitis
CRO/Sponsor: i3 Research
Completed: July 2007

170. **ALCON Protocol: C-05-69**
Safety Study of Olopatadine Nasal Spray
CRO/Sponsor: Alcon Labs
Completed: January 2008

169. **Novartis Protocol: LAF237A23119**
A multi-center, randomized, open-label, active controlled, parallel arm study to compare the efficacy of 12 weeks of treatment with Vildagliptin 100 mg, qd to thiazolidinedione (TZD) as add-on therapy in patients with Type II Diabetes inadequately controlled with metformin monotherapy in a community-based practice setting.
CRO/Sponsor: i3 Research
Completed: November 2007

168. **Genentech Inc. Protocol: Q2948g**
An epidemiologic study of Xolair(omalizumab): Evaluating clinical effectiveness and long- term safety in patients with moderated to severe asthma (EXCELS)
CRO/Sponsor: Genentech, Inc.
Address: South San Francisco, CA 94080-4990 USA
Ongoing

167. **AstraZeneca Protocol: D5896C00021**
A 12-Week, randomized, double-blind, active-controlled, multi-center, phase IIIB study comparing the efficacy

and evaluating the safety of SYMBICORTpMDI 160/45 mcg x 2 actuations twice daily versus budesonide HFA pMDI 160 mcg x 2 actuations twice daily in adult and adolescents (>12 years) Hispanic subjects with asthma
CRO/Sponsor: Parexel International Corporation
Address: Centreville, VA 20120
Completed: May 2008

166. **Sanofi Aventis Protocol: EFC6695**
A multicenter, multi-national, randomized, double-blind, placebo-controlled, study to assess the efficacy and safety of Ciclesonide metered-dose inhaler at 80 mcg BID or 40 mcg BID for 12 weeks in patients aged 4 to <12 years with persistent asthma.
CRO/Sponsor: Omnicare
Address: King of Prussia, PA 19406
Completed: April 2008

165. **SkyPharma Protocol: Sky2028-3-002**
A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12- Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm100/10 mcg twice daily) in a Single Inhaler (SkyePharma HFA pMDI) with Administration of Fluticasone (100 mcg twice daily) and Formoterol (10 mcg twice daily) Alone in Adolescent and Adult Patients with Mild to Moderate Asthma.
CRO/Sponsor: MDS Services
Address: St. Laurent, Quebec
Completed: April 17, 2008

164. **Merck & Co., Inc Protocol: 336-00**
A multicenter, double-blind, placebo controlled, randomized, parallel-group study to evaluate the clinical effect of oral Montelukast versus placebo in persistent asthma which is also active during allergy seasons in pediatric patients with seasonal aeroallergen sensitivity.
CRO/Sponsor: Merck & Co
Address: South San Francisco, CA 94080-4991 USA
Completed: August 2007

163. **Genentech Protocol: Q2982g**
A prospective, randomized, double-blind study of the efficacy of Xolairin atopic asthmatics with good lung capacity who remain difficult to treat. (EXACT)
CRO/Sponsor: Genentech, Inc.
Address: El Paso, TX
Completed: February 2011

162. **University of Texas at El Paso**
Impulse Oscillometric Evaluation of the Effect of Air Quality on Respiratory Function in Normal and Asthmatic Anglo and Hispanic children on the U.S.-Mexico Border
Address: St. Laurent, Quebec
Completed: December 2008

161. **Skye Pharma Protocol: SKY2028-3-004**
A Randomized, double-blind, placebo-controlled, parallel group, stratified, multicenter, 12-week study comparing the safety and efficacy of fluticasone and formoterol combination (FlutiForm100/10mcg or 250/10mcg twice daily) in a single inhaler (SkyPharma HFA pMDI) with the administration of placebo or fluticasone (250 mcg twice daily) and formoterol (10mcg twice daily) alone in adolescent and adult patients with moderate to severe asthma.
CRO/Sponsor: MDS Services
Address: Kansas City, MO
Completed: June 19, 2008

160. **Genentech, Inc. Q3662g**
A phase IIIb multicenter, randomized, double-blind, placebo-controlled study of XolairIn subjects with moderate to severe persistent asthma who are inadequately controlled With high-dose inhaled corticosteroids and long-acting beta-agonists.
CRO/Sponsor: Quintiles, Inc.
Completed: November 2009

159. **Dey, LP 201-070**
A 6-week double-blind, parallel-group, active-controlled trial to compare the efficacy and Safety of concomitant

treatment of formoterol fumarate inhalation solution 20 mcg twice Daily and tiotropium 18 mcg once daily to tiotropium 18 mcg once daily alone in the Treatment of patients with chronic obstructive pulmonary disease.
CRO/Sponsor: PRA International
Address: Lenexa, KS
Completed: January 30, 2007

158. **Novartis Pharmaceuticals Corporation CSPP100A2344**
A 36 week randomized, double-blind, parallel group, multi-center, active-controlled, Optional titration study comparing an aliskiren-based regimen to a lisinopril-base regimen In patients >65 years old with systolic essential hypertension.
CRO/Sponsor: Criterium
Address: East Hanover, NJ
Completed: June 30, 2008

157. **Morton Grove Pharmaceuticals MGP707**
A multi-center, three arm, parallel group, double blind, placebo-controlled, randomized Study of the bioequivalence and efficacy of fluticasone propionate nasal spray (MGP) Compared to FlonaseNasal Spray (GlaxoSmithKline) in patients with seasonal Allergic rhinitis.
Address: Saratoga Springs, NY
Completed: June 2006

156. **Critical Therapeutics, Inc. CTI-04-C05-201**
Assessment of safety, tolerability, and pharmacokinetics of Zileuton injection in patients with asthma. (Phase I/II)
CRO/Sponsor: Paragon Biomedical
Address: Irvine, CA
Completed: July 2006

155. **Astra Zeneca D5899C00001**
A 12-month, double-blind, double-dummy, randomized, parallel group, multicenter efficacy And safety study of SYMBICORTpMDI 2 x 160/4.5 mcg bid and 2 x 80/45 mcg bid Compared to formoterol TBH 2 x 4.5 mcg bid and placebo in patients with COPD.
Address: East Hanover, NJ
Completed: July 2007

154. **Novartis Pharmaceuticals Corporation CSPP100A2327**
An 8-week randomized, double-blind, parallel group, multi-center, placebo and active Controlled dose escalation study to evaluate the efficacy and safety of aliskiren (150 mg And 300 mg) administered alone and in combination with valsartan (160 mg and 320 mg) in Patients with hypertension.
Address: East Hanover, NJ
Completed: September 2006

153. **Novartis Pharmaceuticals Corporation CVAH631D2301**
A 6-week, multicenter, randomized, double-blind, parallel-group study to evaluate the combination of valsartan/HCTZ (160/125 mg with forced titration to a maximum dose of 320/25 mg) compared to valsartan monotherapy (160 mg with forced titration to 320 mg) as initial therapy in patients with severe hypertension.
Address: Morrisville, NC
Completed: August 2006

152. **Sanofi-Aventis XRP1526B-3031**
A multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 mcg administered either in a once-daily in the morning regimen (160 mcg qd AM) for 16 weeks or in a 160 mcg qd AM regimen for 12 weeks preceded by a twice-daily regimen (80 mcg bid) for 4 weeks, or in a 80 mcg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids.
CRO/Sponsor: PPD, Inc
Address: Morrisville, NC
Completed: March 2007

151. **Aventis Pharmaceuticals, Inc. AVE2635A/2003**
A placebo and active controlled, parallel-group, dose-finding study of formoterol fumerate given by dry powder inhalation using the Ultrahalerin adult and adolescent patients with persistent asthma.
CRO/Sponsor: PPD, Inc

Address: East Hanover, NJ
Completed: May 2006

150. **Novartis Pharmaceuticals Corporation CIGE025AUS23**
A 26-week, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the effect of Xolair (omalizumab) on improving the tolerability of specific immunotherapy in patients with persistent allergic asthma.
CRO/Sponsor: Novartis
Address: Kansas City, MO
Completed: February 19, 2008

149. **Centocor, Inc. C0524T03**
A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study evaluating the efficacy and safety of CNTO 148 administered subcutaneously in symptomatic subjects with severe persistent asthma
CRO/Sponsor: Quintiles, Inc.
Completed: August 29, 2007

148. **GlaxoSmithKline, Protocol ADA103578**
A multicenter, randomized, double-blind, triple-dummy, placebo-controlled, parallel group, four-week study assessing the efficacy of fluticasone propionate aqueous nasal spray 200 mcg QD versus montelukast 10 mg QD in adolescent and adult subjects with asthma and seasonal allergic rhinitis who are receiving Advair Diskus100/50 mcg BID or placebo BID.
CRO/Sponsor: GSK ~ RTP, NC
Completed: September 2007

147. **GlaxoSmithKline, Protocol SFA100316**
A stratified, multicenter, randomized, double-blind, parallel group, 4-week comparison of fluticasone propionate/salmeterol DISKUS combination product 100/50 mcg BID versus fluticasone propionate DISKUS 100 mcg BID in pediatric and adolescent subjects with activity-induced bronchospasm.
CRO/Sponsor: GSK ~ RTP, NC
Address: East Hanover, NJ
Completed: Dec 2005

146. **Novartis Pharmaceuticals Corp. Protocol CLAF237A2384**
A multicenter, randomized, double-blind study to compare the effects of 24 weeks treatment with LAF 237 (50 mg qd, 50 mg bid or 100 mg qd) to placebo in drug-naive patients with type 2 diabetes.
CRO/Sponsor: Novartis Pharm.
Address: Morrisville, NC
Completed: May 2006

145. **Sanofi-Aventis Protocol XRP1526B/3030**
A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 mcg administered for 12 weeks either in a once-daily regimen in the morning (160 mcg qd AM) or in a twice-daily regimen (80 mcg bid) in adults and adolescents with mild to moderate persistent asthma treated previously with inhaled corticosteroids.
CRO/Sponsor: PPD
Address: Austin, TX
Completed: Apr 2006

144. **Dynavax Technologies Corporation DV1-SAR-08**
A Phase IIb, Double-Blind, Randomized Study of the Efficacy and Safety and Tolerability Of Subcutaneously Administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (A1C) Plus Antihistamine and Decongestant versus Antihistamine and Decongestant Alone in Ragweed Allergic Children.
CRO/Sponsor: Quintiles, Inc.
Address: Research Triangle Park, NC
Completed: May 2007

143. **GlaxoSmithKline, Protocol FFR30010**
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to Evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X Aqueous nasal spray 50mcg and 100mcg for 2 weeks in pediatric subjects ages 2 to <12 years with seasonal allergic rhinitis (SAR)

CRO/Sponsor: GlaxoSmithKline
Address: Research Triangle Park, NC
Completed: Dec 2005

142. **GlaxoSmithKline, Protocol FFR30008**
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to Evaluate the safety and efficacy of once-daily, intranasal administration of GW685698X Aqueous nasal spray 50mcg and 100mcg for 12 weeks in pediatric subjects ages 2 to <12 years with perennial allergic rhinitis (PAR)
CRO/Sponsor: GlaxoSmithKline
Address: Morrisville, NC
Completed: October 2005

141. **Sanofi-Aventis, Protocol AVE2635A/2001**
A placebo and active-controlled (ciclesonide metered-dose inhaler), randomized, parallel-Group, dose-range finding study of ciclesonide administered by a dry powder inhaler (Ultrahaler in adult and adolescent patients with persistent asthma.
CRO/Sponsor: PPD
Address: Research Triangle Park, NC
Completed: Oct 2005

140. **GlaxoSmithKline, Protocol SFA100062**
A randomized, parallel group, double-blind, comparative trial assessing lung function and o other measures of asthma control in adults and adolescents, at least 12 years of age, with persistent asthma, who have either a B16-Arg/Arg, a B16-Gly/Gly or a B-16 Arg/Gly genotype and are treated with fluticasone propionate/salmeterol diskuscombination product 100/50mcg or salmeterol diskus50mcg BID
CRO/Sponsor: GlaxoSmithKline
Address: East Hanover, NJ
Completed: June 2006

139. **Novartis, Protocol CLAF237A2355**
A multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with combination therapy of LAF237 and Pioglitazone to LAF237 monotherapy or Pioglitazone monotherapy in drug-naive patients with type 2 diabetes.
CRO/Sponsor: Novartis Pharmaceuticals
Address: East Hanover, NJ
Completed: Feb 2006

138. **Novartis, Protocol CSPP100A2307**
An eight week, randomized, double-blind, parallel group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with ramipril in patients with hypertension and diabetes mellitus.
CRO/Sponsor: Novartis Pharmaceuticals
Address: East Hanover, NJ
Completed: Nov 2005

137. **Novartis, Protocol CLAF237A2301 E1**
A 28-week extension to a multicenter, randomized, double-blind study to compare the effects of 24 weeks treatment with LAF237 (50mg qd, 50 mg bid, or 100 mg qd) to placebo in drug-naive patients with type 2 diabetes
CRO/Sponsor: Novartis Pharmaceutical
Address: Overland Park, KS
Completed: May 2006

136. **GlaxoSmithKline, Protocol P2200313**
A Safety Study of a Topical Corticosteroid Cream in Pediatric Subjects Aged 3 years to 5 years 11 months with Atopic Dermatitis
CRO/Sponsor: Bailer Pharma
Address: Overland Park, KS
Completed: January 2005

135. **GlaxoSmithKline, Protocol P2200314**
A Safety Study of a Topical Corticosteroid Cream in Pediatric Subjects Aged 3 Months to 35 months with Atopic Dermatitis.

CRO/Sponsor: Bailer Pharma
Address: East Hanover, NJ
Completed: January 2005

134. **Novartis, Protocol CLAF237A2301**
A multicenter, randomized, double-blind study to compare the effects of 24 weeks Treatment with LAF237 (50 mg qd, 50 mg bid or 100 mg qd) to placebo in drug-naive patients with type 2 diabetes.
CRO/Sponsor: Novartis
Address: Wilmington, NC
Completed: May 2006

133. **Aventis Pharmaceuticals, Protocol XRP1526B 3027**
A multi-center, multinational, randomized, double-blind, parallel group study of the effects of Ciclesonide HFA-MDI 640 mcg/day and Beclomethasone HFA-MDI 640 mcg/day on Lens Opacification in adult subjects with moderate to severe persistent asthma
CRO/Sponsor: PPD Development
Completed: August 2005

132. **Dey, L.P. Protocol DL-059**
A 12-week, double-blind, parallel-group, placebo and active controlled trial to evaluate the efficacy and safety of formoterol fumerate inhalation solution 20 mcg in the treatment of patients with chronic obstructive pulmonary disease; Followed by a 40-week open-label safety extension.
CRO/Sponsor: i3 Research
Address: Cary, NC
Completed: Jan 2006

131. **GlaxoSmithKline, Protocol FLS-R28**
A double-blind, randomized, controlled trial comparing the efficacy of treatment with Fluticasone Nasal Spray to Placebo in Adult Subjects with Allergic Rhinitis and History of Sleep Disturbance on Cognitive Performance and Daytime Sleepiness.
CRO/Sponsor: Western Sky Medical Research Grant
Completed: July 2004

130. **Aventis Pharmaceuticals, Protocol AVE0547A2001**
A Twelve week, randomized, double-blind, parallel group trial comparing the efficacy, safety, and tolerability of a 20mg daily dose of IPL512, 602 oral tablets to placebo in subjects with mild to moderate persistent asthma.
CRO/Sponsor: Kendle Int.
Address: Cincinnati, OH
Completed: April 2004

129. **Astra Zeneca Protocol D5896C0001**
A Randomized, double-blind, active-controlled, parallel-group, single-dummy, multicenter, 12 week study to assess the efficacy and safety of SymbicortpMDI 160/45 mcg x 2 actuations once-daily compared to Symbicort pMDI 80/45 mcg x 2 actuations QD, Symbicort pMDI 80/45 mcg x 2 actuations
CRO/Sponsor: Target Research
Address: Philadelphia, PA
Completed: January 2005

128. **Astra Zeneca Protocol SD-039-0717**
A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of Symbicort(160/45 mcg) versus its Mono-Products (budesonide and formoterol) in Adolescents (>12 Years of Age) and Adults with Asthma SPRUCE 160/45
CRO/Sponsor: PPD Development
Address: Wilmington, NC
Completed: March 2004

127. **Schering-Plough Study P03284-35**
Efficacy and safety Of Desloratadine 10 mg daily versus Placebo in Subjects with Allergic Airway~ Disease During the Pollen Season
CRO/Sponsor: Integrated Therapeutics Group, Inc.
Address: Kenilworth, NJ
Completed: December 2004

126. **Altana Byk Gulden Protocol BY217/FK1 021**
12 Weeks Tr0atment with 125 mcg Roflumilast versus 250 mcg Roflumilast versus Placebo in Patients with Asthma.
Address: Altana Inc. Melville, NY
Completed: April 2004

125. **Astra Zeneca Protocol SD-039-0718**
A Twelve-Week, Randomized, Double-Blind, Double-Dummy Trial of Symbicort (40/45 mcg) versus its Mono-Products (budesonide and Formoterol) in Asthmatic Children Aged Six to Fifteen Years-SEEDLINGS 40/45
CRO/Sponsor: PPD Development, Inc.
Address: Morrisville, NC
Completed: December 2003

124. **Forest Research Institute Protocol ANC-MD-17**
Double Blind Study of the Efficacy, Safety, and Pharmacoeconomics of Flunisolide HFA Inhaler System as Compared to Fluticasone Inhalation Aerosol in Patients with Asthma.
CRO/Sponsor: Forest Research Institute
Address: Jersey City, New Jersey
Completed: January 2004

123. **Aventis Pharmaceuticals Protocol XRG50291/6004**
The Benefit of Nasacort AQin Adult Subjects with Allergic Rhinitis and Suspected Associated Sleep Breathing Disorders.
CRO/Sponsor: Western Sky Medical Research Grant
Completed: July 2004

122. **Astra-Zeneca Protocol SD-004-0726**
A Placebo-Controlled Comparison of the Efficacy, Safety and Pharmacokinetics of the Current US Version of Pulmicort (Budesonide) Turbohalerand the New Version of Pulmicort Turbohalerin Asthmatic Children and Adolescents.
CRO/Sponsor: ICON Clinical Research
Address: Newark, DE
Completed: July 2004

121. **Aventis Pharmaceuticals Protocol M016455P/3002**
A Multi-Centers Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study To Assess the efficacy and Safety of Fexofenadine 120 mg in Subjects with Mild to Moderate Persistent Asthma.
CRO/Sponsor: Quintiles, Inc.
Address: Kansas City, MO
Completed: Jun 2003

120. **Pfizer, Inc. Protocol A00661078**
A Multi-Center, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR versus Levofloxacin for the Treatment of Acute Bacterial Maxillary Sinusitis In Adults Undergoing Diagnostic Sinus Aspiration.
CRO/Sponsor: RPS, Inc.
Address: Blue Bell, PA
Completed: April 2004

119. **Longwood Pharmaceutical-Tedor Pharma Inc. - Protocol LPR-A023-C1**
A Single-Dose, Randomized, Double-Blind, Double-Dummy, 6-Period, Crossover, Placebo-Controlled, Phase I/II, Dose-Ranging Study Comparing the Efficacy and Safety of 75, 100, and 200 mcg per Capsule of Albuterol Sulfate Dry Powder Delivered via a Dry Powder Inhaler (FlowcapsInhaler) and 108 and 216 mcg (ex-Actuator) of Albuterol Sulfate via Metered-Dose Inhaler in Patients with Asthma.
CRO/Sponsor: PPD Development, Inc.
Address: Morrisville, NC
Completed: December 2004

118. **Forest Laboratories, Inc. Protocol ANC-MD-21**
An In-Use Study of the Dose Indicator for the Flunisolide HFA Inhaler System.
CRO/Sponsor: Forest Laboratories, Inc.
Address: Jersey City, NJ

Completed: June 2003

117. **AstraZeneca LP Protocol SD-039-0719**
A Six-Month, Randomized, Open-Label Safety Study of Symbicort~ (160/45 mcg) Compared to Pulmicort Turbohalerin Asthmatic Children Aged Six to Eleven Years - SAPLING
CRO/Sponsor: PPD Development, Inc.
Address: Morrisville, NC
Completed: August 2003

116. **AstraZeneca LP Protocol SD-039-0716**
A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of Symbicort (80/45 mcg) versus its Mono-Products (budesonide and Formoterol) in Children (> 6 Years of Age) and Adults with Asthma SPRUCE 80/45
CRO/Sponsor: PPD Development, Inc.
Address: Morrisville, NC
Completed: December 2003

115. **GlaxoSmithKline~ Protocol SAS30021**
A Stratified, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 12-week Trial Evaluating the Safety and Efficacy of the Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50 mcg Once Daily Versus Fluticasone Propionate DISKUS Once Dally in Placebo and Symptomatic Pediatric Subjects (4 to 11 Years) With Asthma.
CRO/Sponsor: PRA International
Address: Lenexa, KS
Completed: November 2003

114. **AstraZeneca Pharmaceuticals Protocol DX-RES-2103**
An Evaluation or the effectiveness of Pulmicort Respules(budesonide inhalation Suspension) vs. Singulair(Montelukast sodium) in children 2-8 years old with Asthma requiring controller therapy.
CRO/Sponsor: Target Research Associates
Address: Philadelphia, PA
Completed: January 2005

113. **AstraZeneca Pharmaceuticals Protocol SD-NEE-0003**
A Randomized, Double-Blind, Parallel-Group Multicenter Efficacy and Safety Phase IIB Pilot Study of Esomeprazole 40 mg Twice Daily Versus Placebo Twice Daily in Adult Asthmatics Treated for 4 months.
CRO/Sponsor: RPS, Inc.
Address: Plymouth Meeting, PA
Completed: March 2004

112. **GlaxoSmithKline Protocol FAS30030**
A Randomized (2:1), Stratified, Double-Blind, Parallel-Group, Placebo-Controlled, 12-Week, Multi-Center Trial of Fluticasone Propionate HFA Inhalation Aerosol 88mcg BID versus Placebo HFA Delivered via an MDI and a Valved Holding Chamber with Facemask in Pediatric Subjects 1 to <4 Years of Age with Asthma.
CRO/Sponsor: Ingenix, Inc.
Address: Basking Ridge, NJ
Completed: December 2003

111. **Aventis Pharmaceuticals Protocol XRP1526B-343**
A Phase III~ Multicenter, Double-Blind, Placebo Controlled, Non-Inferiority Study Assessing the Effects of Ciclesonide Metered Dose Inhaler 50 mcg/Day and 200 mcg/Day (Ex-Valve) Administered Once Daily on Growth in Children with Mild Persistent Asthma.
CRO/Sponsor: Quintiles, Inc.
Address: Kansas City, MO
Completed: December 2003

110. **Aventis Pharmaceuticals Protocol XRP1526B-341 LT**
A Multicenter, Randomized, Open-Label, One Year Long-Term Safety Study of Ciclesonide Metered Dose Inhaler 50 mcg/Day to 200 mcg/Day (Ex-Valve) Administered Twice Daily or Fluticasone Dry Powder Inhaler (FloventRotadisk 50 mcg or 100 mcg Administered Twice Daily For the Treatment of Children with Persistent Asthma.
CRO/Sponsor: Quintiles, Inc

Address: San Diego, CA
Completed: December 2003

109. **Aventis Pharmaceuticals Protocol XRP1526B-341**
A Phase III Double Blind, Placebo Controlled, Parallel Group, Multicenter, Efficacy, Safety and Dose Response Study of Ciclesonide Metered Dose Inhaler 50 mcg/Day, 100 mcg/Day, and 200 mcg/Day (Ex-Valve) Administered Once Daily for 12 Weeks in the Treatment of Children with Persistent Asthma.
CRO/Sponsor: Quintiles, Inc.
Address: San Diego, CA
Completed: December 2002

108. **Aventis Pharmaceuticals Protocol XRP1S26B-326**
A Multicenter, Open-Label, Long-Term (1 year) Safety Study of Ciclesonide 100 mcg/Day to 400 mcg/Day (Ex-Valve) Metered Dose Inhaler Administered Once Daily For The Treatment of Mild to Moderate Persistent Asthma in Adolescents and Adults.
CRO/Sponsor: Quintiles, Inc.
Address: Kansas City, MO
Completed: August 2003

107. **Aventis Pharmaceuticals Protocol XRP1526B-325**
A Phase III Double-Blind, Parallel Group, Multicenter, Placebo-Controlled Study of Ciclesonide MDI 800 mcg/Day and 1600 mcg/Day Administered Twice Daily for 12 Weeks to Determine the Effectiveness of Ciclesonide to Reduce Oral Corticosteroid (OCS) Use in Oral Corticosteroid-Dependent Patients with Severe Persistent Asthma.
CRO/Sponsor: Quintiles, Inc.
Address: Kansas City, MO
Completed: November 2002

106. **Novartis Pharmaceuticals Protocol CF0R258D2307**
A Randomized, Multicenter, Placebo-Controlled Parallel Group Study of Four months Duration per patient to Evaluate the Safety and Efficacy of Treatment with 24 mcg b.i.d. and 12 mcg b.i.d. Formoterol, double-blind, and 12 mcg b.i.d. Formoterol with additional on demand Formoterol doses, open-label, in adolescent and adult patients with persistent stable asthma.
CRO/Sponsor: Novartis
Address: East Hanover, NJ
Completed: May 2004

105. **Aventis Pharmaceuticals Protocol RPR201745-202**
A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter, Pilot Efficacy and Safety Study of RPR201745 Administered by Inhalation Twice Daily for Twelve Weeks in Adults with Mild to Moderate Persistent Asthma
CRO/Sponsor: Kendle International
Address: Cincinnati, OH
Completed: July 2002

104. **Aventis Pharmaceuticals Protocol XRP1526B-323LT**
A Multicenter, Double-Blind, Randomized, One Year, Long-Term Safety Study of Ciclesonide 400 mcg/Day to 800 mcg/Day (Ex-valve) or QVAR 320 mcg/Day to 640 mcg/Day (Ex-Actuator) Metered Dose Inhaler Administered Twice Daily For the Treatment of Severe Persistent Asthma in Adolescents and Adults.
CRO/Sponsor: Quintiles, Inc.
Address: San Diego, CA
Completed: November 2003

103. **Aventis Pharmaceuticals Protocol XRP1526B-323**
A Phase III Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Placebo Controlled, Efficacy and Safety Study of Ciclesonide MDI 400 mcg/Day, 800 mcg/ Day (Ex-Valve) and FloventMDI (Fluticasone Propionate) 880 mcg/Day (Ex-Actuator) Administered twice Daily for 12-Weeks In The Treatment of Severe Persistent Asthma in Adolescents and Adults
CRO/Sponsor: Quintiles
Address: San Diego, CA
Completed: December 2002

102. **GlaxoSmithKline Protocol 5A530022**

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-week Trial Evaluating the Efficacy and Safety of the Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Once Daily Versus Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50 mcg Twice Daily Versus Placebo in Symptomatic Adolescent and Adult Subjects with Asthma that is Not Controlled on short-Acting Beta 2-Agonists Alone
CRO/Sponsor: PRA International
Address: Lenexa, KS
Completed: May 2003

101. **Altana Byk Gulden Protocol BY217/FK1 020**
12 Weeks Treatment with 250 mcg Roflumilast Versus Placebo in Patients with Asthma.
CRO/Sponsor: Altana
Address: Parsippany, NJ
Completed: December 2002

100. **Aventis Pharmaceuticals Protocol M016455A/4122**
A Double-Blind, Double-Dummy, Parallel-Group, Multi-Center, Randomized, Study of Fexofenadine IICL 180 mg vs. Cetirizine HCL 10 mg in Subjects with Moderate to Severe Seasonal Allergic Rhinitis (SAR) During the Fall Allergy Season.
CRO/Sponsor: Aventis
Address: Bridgewater, NJ
Completed: July 2002

99. **Aventis Pharmaceuticals Protocol XRP1S26B-322**
A Phase III Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Efficacy, Safety and Dose Response Study of Ciclesonide Metered Dose Inhaler 100 mcg/Day, 200 mcg/Day, and 400 mcg/Day (Ex-valve) Administered Once Daily for 12 weeks in the Treatment of Mild to Moderate Persistent Asthma in Adolescents and Adults.
CRO/Sponsor: Quintiles
Address: San Diego, CA
Completed: December 2002

98. **Dey L.P. Protocol DL-047**
A Double-Blind, Double-Dummy, Randomized, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of Dey Beclomethasone Dipropionate Monohydrate Nasal Spray 0.042% in Adolescent and Adult Patients with Seasonal Allergic Rhinitis.
CRO/Sponsor: Target Research
Completed: November 2001

97. **Genentech, Inc. Protocol Q2195g**
An Open-Label Extension Study of Xolair (Omalizumab) in Moderate to Severe, Persistent Asthma Subjects whoCompleted Study Q2143g (ALTO)
CRO/Sponsor: CTMS, Inc.
Address: Bristol, TN
Completed: July 2002

96. **EPIMRD, Inc. Protocol AZ-415**
An Evaluation of Sleep and Growth Hormone Secretion in Children with Nasal Congestion from Allergic Rhinitis Before and After Therapy with Intranasal Budesonide.
Completed: August 2002

95. **EPIMRD, Inc. Protocol M016455/1EO5**
A Double Blind, Double Dummy, Placebo Controlled Study of the Effect of Diphenhydramine 50 mg and Fexofenadine 180 mg on the Test of Variable Attention (TOVA).
Completed: March 2001

94. **Schering Plough (ITGI) Protocol P02067**
A Study of the Effects of Desloratadine on the Quality of Life of Subjects with Disordered Sleep Associated with Symptomatic Seasonal Allergic Rhinitis (SAR)
CRO/Sponsor: BRCI, Inc.
Address: Dexter, Michigan
Completed: October 2001

93. **Glaxo Wellcome Protocol SMS40314**
A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel Group, 8 Week Comparison Of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Salmeterol Xinafoate plus Ipratropium Bromide Versus Placebo in Subject with Chronic Obstructive Pulmonary Disease.
CRO/Sponsor: CTMS, Inc.
Address: Bristol, TN
Completed: June 2002

92. **Aventis Pharmaceuticals Protocol XRP1526B-322**
A Phase III Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Efficacy, Safety and Dose Response Study of Ciclesonide Metered Dose Inhaler 100 mcg/Day, 200 mcg/Day, and 400 mcg/Day (Ex-valve) Administered Once Daily for 12 weeks in the Treatment of Mild to Moderate Persistent Asthma in Adolescents and Adults.
CRO/Sponsor: Quintiles
Completed: April 2003

91. **Dey L.P. Protocol DL-047**
A Double-Blind, Double-Dummy, Randomized, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of Dey Beclomethasone Dipropionate Monohydrate Nasal Spray 0.042% in Adolescent and Adult Patients with Seasonal Allergic Rhinitis.
CRO/Sponsor: Target Research
Address: San Diego, CA
Completed: November 2001

90. **Abbott Laboratories Protocol M00-225**
Comparative Study of the Safety and Efficacy of ABT-773 150 mg QD vs. 150 mg BID for the Treatment of Acute Bacterial Sinusitis.
CRO/Sponsor: The Phoenix
Address: Mt. Arlington, New Jersey
Completed: May 2001

89. **Bayer Corporation Protocol 100288**
Prospective, Randomized, Double-Blind, Three-armed, Multicenter, Comparative Trial to Evaluate the Efficacy and Safety of Faropenem daloxate 300 mg P0 BID for 7 days vs. Faropenem Daloxate 300mg P0 BID for 10 days vs. Cefuroxime Axetil 250 mg P0 BID for 10 days in the Treatment of Acute Bacterial Sinusitis.
CRO/Sponsor: MTRA, Inc.
Address: Natick, Massachusetts
Completed: November 2001

88. **Glaxo Wellcome Protocol FAP30008**
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 12-week Trial of Inhaled Fluticasone Propionate 88 mcg BID, 220 mcg BID and 440 mcg BID versus Placebo in Propellant GR 106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Bronchodilator Therapy
CRO/Sponsor: Kendle, Int.
Address: New Jersey
Completed: August 2001

87. **Glaxo Wellcome Protocol FAP30007**
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-week Trial of Inhaled Fluticasone Propionate 88 mcg BID, 220 mcg BID and 440 mcg BID versus Placebo in Propellant GR 106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Inhaled Corticosteroid Therapy.
CRO/Sponsor: Kendle, Int.
Address: New Jersey
Completed: August 2001

86. **Schering-Plough Research Institute Protocol P0 1997**
Efficacy and Safety of Combination Loratadine/Montelukast QD vs. its Components in the Treatment of Subjects with Seasonal Allergic Rhinitis.
CRO/Sponsor: Ingenex Pharmaceutical Services
Address: Chatham Township, NJ
Completed: January 2001

85. **Glaxo Wellcome, Inc. Protocol FPD 40010**

A Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate Inhalation Powder (250 mcg QD) and Placebo in Subjects at Least 12 Years of Age with Chronic Asthma Currently Treated with Inhaled Corticosteroids.
CRO/Sponsor: PharmaResearch Corporation
Address: Wilmington, NC
Completed: March 2001

84. **Aventis Pharmaceuticals Inc.**
T.A.R.G.E.T. fl "The Allegra Research on Gaining Experience Trial ll"
CRO/Sponsor: Pharmaceutical Research Associates, Inc.
Address: Lenexa, Kansas
Completed: May 2000

83. **Fujisawa Healthcare, Inc. Protocol 99-0-054**
An Open-Label Study to Evaluate the Safety of Topically Applied Tacrolimus Ointment for .the Treatment of Atopic Dermatitis
Completed: June 2001

82. **Glaxo Wellcome Protocol SAS40021**
A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100 mcg BID Via the DISKUS Inhaler Versus Oral Montelukast 10mg QD in Adolescents and Adults with Persistent Asthma.
CRO/Sponsor: Clinical Trial Management Services, Inc.
Address: Bristol, Tn.
Completed: September 2000

81. **Glaxo Wellcome Protocol FPD40009**
A Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate Inhalation Powder (250 mcg QD) and Placebo in Subjects at least 12 years of age with Chronic Asthma Currently Receiving Short Acting Beta Agonist Alone.
CRO/Sponsor: PharmaResearch Corporation
Address: Wilmington, NC
Completed: February 2001

80. **Schering-Plough Protocol P00214**
Efficacy and Safety of SCH 034117 in Subjects with Seasonal Allergic Rhinitis and Concurrent asthma.
CRO/Sponsor: Kern McNeill International
Completed: March 2000

79. **Abbott Laboratories - Study M99-066**
A Comparative Study of the Safety, Efficacy and Effectiveness of Clarithromycin Extended-Release Tablets and Augmentin Tablets for the Treatment of Subjects With Acute Exacerbation of Chronic Bronchitis.
CRO/Sponsor: Paragon Biomedical
Address: Irvine, CA
Completed: April 2000

78. **Abbott Laboratories Study M99-053**
Evaluation of the Safety and Efficacy of Three Oral Doses of ABT-773 for the Treatment of Acute Maxillary Sinusitis.
CRO/Sponsor: Paragon Biomedical
Address: Irvine, CA
Completed: May 2000

77. **Schering-Plough Study P00217**
A Double-Blind, Placebo-Controlled Study With DLC (SCH 34117) In The Treatment Of Subjects >12 Years of Age With Perennial Allergic Rhinitis.
CRO/Sponsor: Quintiles, Inc.
Completed: January 2000

76. **Pfizer Inc. Study 253-102**
Phase IIA Multicenter, Randomized, Double-Blind, Double-Dummy, Active and Placebo-Controlled, Parallel Group, Dose-Response Study of the Efficacy, Safety, and Tolerability of six weeks Oral Dosing with 0-13,610 Compared

to Montelukast and Placebo In Adults with Persistent Asthma.
CRO/Sponsor: Clinical Trials Management Services, Inc.
Address: Bristol, Tn.
Completed: December 1999

75. **Schering-Plough Study P00105-15**
A Study to Compare the Efficacy and Safety of Claritin-D24 Hour Extended Release Tablets and Allegra-Din Subjects with Seasonal Allergic Rhinitis (SAR)
CRO/Sponsor: Integrated Therapeutics Group, Inc. ~ Biopharmaceutical Research Consultants, Inc.
Address: Ann Arbor, Michigan
Completed: May 1999

74. **Eli Lilly and Company Study B3M-MC-AJBA**
Cefaclor vs. Cefuroxime Axetil in Difficult to Treat Acute Otitis Media
CRO/Sponsor: PPD Pharmaco
Address: Wilmington, North Carolina
Completed: May 1999

73. **Bayer Pharmaceutical Study 100161**
Prospective, Randomized, Double-Blind, Comparison of the Safety and Efficacy of Oral Moxifloxacin (BAY 12-8039) 400 mg QD for 10 days Versus Oral Trovafloxadn 200 mg QD for 10 days in the Treatment of Patients with Acute Bacterial Maxillary Sinusitis.
CRO/Sponsor: Medical & Technical Research Associates, Inc.
Address: Natick, Massachusetts
Completed: February 1999

72. **Schering-Plough Study P97-293**
A Double-Blind Placebo-controlled Study to Evaluate the Effects of Treatment of Seasonal Allergic Rhinitis (SAR) in Subjects with Co-morbid Asthma and a History of Seasonal Exacerbations of Asthma on Medical Resources Utilization (for Asthma and SAR)
CRO/Sponsor: Integrated Therapeutics Group, Inc. ~ CRO-BCRI
Address: Kenilworth, New Jersey
Completed: January 1999

71. **TAP Holdings, Inc. Study CEF-97-006**
Comparative Safety and Efficacy of Cefditoren Pivoxil and Amoxlcillin/Clavulanate (Augmentin) In the Treatment of Community-Acquired Pneumonia.
CRO/Sponsor: Paragon Biomedical
Address: Deerfield, IL
Completed: February 2000

70. **Wallace Laboratories Study 368**
A Randomized, Double-Blind Study of Astelin Nasal Spray Monotherapy versus Combination Therapy of A Nasal Steroid and Oral Antihistamine in Subjects with Seasonal Allergic Rhinitis.
CRO/Sponsor: Wallace Laboratories
Address: Cranbury, NJ
Completed: June 1998

69. **Rhone-Poulenc Rorer Study RGSO16Y-204**
A Phase II/III Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Efficacy, Safety and Dose Response Study of Azmacort (triamcinolone acetonide) HFA-134a Inhalation Aerosol 225 mcg, 450 mcg, and 900 mcg Administered Once Daily for 12 Weeks in the Treatment of Mild Persistent and Moderate Persistent Asthma in 800 Adolescents and Adults.
CRO/Sponsor: Paragon Biomedical
Address: Abbott Park, IL
Completed: October 1998

68. **Abbott Laboratories - Study M97-756**
A Comparative Study of the Efficacy and Safety of Clarithromycin Extended Release Tablets and Clarithromycin Immediate Release Tablets for the Treatment of Subjects with Acute Exacerbation of Chronic Bronchitis.
CRO/Sponsor: Abbott Laboratories
Address: Abbott Park, IL

Completed: March 1999

67. **Abbott Laboratories - Study M97-754**
A Comparative Study of the Efficacy and Safety of Clarithromycin Extended Release Tablets and Loracarbef Pulvules for the Treatment of Subjects with Secondary Bacterial Infections of Acute Bronchitis.
CRO/Sponsor: Abbott Laboratories
Address: Abbott Park, IL
Completed: December 1998

66. **Glaxo-Wellcome, Inc. Study NAXA 3002**
A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of Inhaled Zanamivir (GG167) 10 mg Administered Twice a Day for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Adolescents and Adults.
CRO/Sponsor: Glaxo Wellcome, Inc.
Address: Research Triangle Park, NC
Completed: March 1998

65. **Abbott Laboratories Study M97-680**
A Study of the Genetic Component of ALT Elevations in Patients Previously Treated with Zileuton (Zyflo).
CRO/Sponsor: Abbott Laboratories
Address: Abbott Park, IL
Completed: September 1997

64. **Hoechst Marion Roussel Fexofenadine Study**
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Study Comparing the Efficacy and Safety of Four Dosage Strengths of Fexofenadine HCl (20, 60, 120, & 240 mg BID) in the Treatment of Chronic Idiopathic Urticaria.
CRO/Sponsor: Paragon Biomedical
Address: Kansas City, MO
Completed: June 1997

63. **Abbott Laboratories - Study M95-337**
Phase III Study of the Efficacy of Zileuton 1200 mg BID, Controlled Release (CR), and 600 mg QID, Immediate Release (IR), and Placebo in Patients with Moderate Asthma.
CRO/Sponsor: Covance
Address: Abbott Park, IL
Completed: August 1997

62. **SmithKline Beecham Pharmaceutical Study SB 205312/070**
A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Two Doses of SB 205312 Administered as an Oral Suspension (75 mg BID and 150 mg BID) for 12 weeks in Pediatric Out-Patients with Asthma.
CRO/Sponsor: ClinTrials Research
Address: Collegeville, PA
Completed: July 1997

61. **Abbott Laboratories - Study M96-452**
Phase III Study of ABT-761 in Patients Completing Protocol M95-411
CRO/Sponsor: Paragon Biomedical
Address: Abbott Park, IL
Completed: January 1996

60. **Abbott Laboratories-Study M95-411**
Phase III Study of the Safety and Efficacy of Abt-761 150 mg, 300 mg, QD VS Placebo in Moderate Asthma.
CRO/Sponsor: Paragon Biomedical
Address: Abbott Park, IL
Completed: January 1996

59. **SmithKline Beecham Pharmaceuticals Study SB 2053 12/080**
A Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Study to Examine the Effects of Oral SB 205312 300 mg BID in Patients with Asthma and concomitant Seasonal Allergic Rhinitis a Comparison to Patients taking Vanceril 168 mcg BID and as Required Nasal Rescue Medication.

CRO/Sponsor: ClinTrials Research, Inc.
Address: Collegeville, PA
Completed: November 1996

58. **SmithKline Beecham Pharmaceuticals Study 205312/087**
A Multi-Center, Open Label, Long-Term Study of the Safety, tolerability, and Efficacy of Oral SB 205312 in Pediatric Patients with Mild to Moderate Asthma.
CRO/Sponsor: ClinTrials Research, Inc.
Address: King of Prussia, PA
Completed: May 1997

57. **SmithKline Beecham Pharmaceuticals Study 205312/084**
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to evaluate the Safety and Efficacy of Oral Twice-Daily Administration of SB 205312 in Pediatric Patients with Mild to Moderate Asthma
CRO/Sponsor: SmithKline Beecham Pharmaceuticals
Address: King of Prussia, PA
Completed: May 1996

56. **Rhone-Poulenc-Rorer Study RG 5016T 303**
A Long Term Safety Study of Azmacort HFA-134a and Azmacort Forte HFA-134a Oral Inhaler in the Treatment of Adult Asthmatics
CRO/Sponsor: Rhone-Poulenc-Rorer
Address: Collegeville, PA
Completed: 1996

55. **Rhone-Poulenc-Rorer Study RG 5016T 203**
A Double Blind, Dose Ranging Study of Azmacort HFA-134a Oral Inhaler Compared to Azmacort Oral Inhaler in the Treatment of Asthma in Children
CRO/Sponsor: Rhone-Poulenc-Rorer
Address: Collegeville, PA
Completed: 1996

54. **Pfizer Central Research Study 167-102**
Phase II Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of Six Weeks Treatment with Oral 0-11,974 in Adults with Mild to Moderate Asthma.
CRO/Sponsor: Pfizer Central Research
Address: Groton, CT
Completed: January 1996

53. **The Upjohn Company Study M/1140/108**
Oral Cefpodoxime Proxetil (VANTIN) Tablets In the Treatment of Acute Maxillary Sinusitis in Adults: Sinus Aspiration Study
CRO/Sponsor: The Upjohn Company
Address: Kalamazoo, MI
Completed: May 1997

52. **Smith Kline Beecham Study 205312/012**
A Multicenter, Double Blind, Placebo Controlled, Parallel Group Comparison of Safety and Efficacy or Oral Twice Daily Administration of SB 205312 with Inhaled Tilade in Patients with Mild to Moderate Asthma.
CRO/Sponsor: SmithKline Beecham Pharmaceuticals
Address: King of Prussia, PA
Completed: December 1995

51. **Abbott Laboratories Study M94-184**
Comparative Cost Effectiveness Study of Clarithromycin, Erythromycin Stearate and Cefaclor in the Treatment of Lower Respiratory Tract Infections
CRO/Sponsor: Abbott Laboratories ~ PACT
Address: Abbott Park, IL
Completed: January 1995

50. **Abbott Laboratories Study M94-199**
Long Term surveillance Study of Zileuton Plus Usual Care versus Usual Care in Patients with Asthma.

CRO/Sponsor: Abbott Laboratories ~ Paragon Biomedical
Address: Abbott Park, IL
Completed: February 1997

49. **Astra USA Study RPM 2439**
Randomized, Open-Label Comparative Study of Rhinocort (Budesonide) Nasal Inhaler
Completed: Aug 1994

48. **Roberts Pharmaceuticals Study 30, 722-301 B**
A Double Blind Phase III Evaluation of Doxofylline, Theophylline, and Placebo in Patients with Chronic Reversible Asthma.
CRO/Sponsor: Roberts Pharmaceutical Corp.
Address: East Hanover, NJ.
Completed: Nov 1994

47. **Broncorp, Inc**
A Double Blind Placebo Controlled Study to Evaluate Low Dose Parenteral Cyanocobalmin in Lowering Total Serum IgE Levels and Decreasing Symptoms of Allergic Rhinitis
CRO/Sponsor: Broncorp, Inc
Address: Trout Lake, WA
Completed: Sept 1993

46. **Schering**
Proventil Repetabs in the Prevention of Nocturnal Asthma.
CRO/Sponsor: Schering, Inc.
Address: Kenilworth, NJ
Completed: Nov 1992

45. **The Upjohn Company Study M/1140/0045**
The Study of Cefpodoxime in the Treatment of Acute Maxillary Sinusitis.
CRO/Sponsor: The Upjohn Company
Address: Kalamazoo, MI
Completed: Jan 1993

44. **Pfizer, Inc. Study 134-103-507**
The effect of CP-85,958 on a specific antigen, inhalation challenge with patients with bronchial asthma.
CRO/Sponsor: Pfizer, Inc.
Address: Groton, CT 06340
Completed: Jan 1993

43. **Abbott M90-483**
A Multicenter, double-blind, randomized, comparative study of the efficacy and safety of Temafloxacin 600 mg BID and Ceclor 500 mg QIB in the treatment of patients with bacterial infection of the lower respiratory tract. RTI Research Triangle Park, NC
Completed: June 1991

42. **Ciba-Geigy, Inc Study 04**
A double-blind, multiple dose, dose-finding trial of Formoterol suspension aerosol vs. placebo in patients with reversible obstructive airway disease.
CRO/Sponsor: Ciba-Geigy
Address: Summit, NJ
Completed: 1991

41. **G.D. Searle & Co. S81-89-02-053**
Double-blind, placebo controlled, comparative study of the efficacy and safety of three dosage regimens of Misoprostol in the prevention of Nsaid-induced gastric ulcers.
CRO/Sponsor: Pharmaco
Address: Austin, TX
Completed: December 1991

40. **Rhone-Poulenc-Rorer RGW-5016-112**
An Efficacy Trial of Comparable Plasma Concentrations of Triamcinolone Acetonide given by inhalation (Azmacort) and Intramuscular Injection (Kenalog-40) in the Management of Moderate Asthmatics

CRO/Sponsor: Rhone-Poulenc-Rorer
Address: Collegeville, PA
Completed: October 1991

39. **Abbott M90-435**
P.A.C.T. ~ Clarithromycin vs. Cefaclor in Acute Exacerbation of Chronic Bronchitis
CRO/Sponsor: Abbott Laboratories
Address: Abbott Park, IL
Completed: July 1991

38. **Upjohn M/1140/0045**
Comparison of Oral Cefadoximine Praxetil (Doxef tablets) with Oral Amoxicillin/Clavunate (Augmentin) in the Treatment of Acute Maxillary Sinusitis in Adults
CRO/Sponsor: The Upjohn Company
Address: Kalamazoo, MI
Completed: December 1991

37. **Eli Lilly B9U -MC-AQAB**
Disithromycin vs. Erythromycin in the Treatment of Acute Exacerbation of Chronic Bronchitis and Pneumonia.
CRO/Sponsor: D.R.A.C.
Completed: January 1991

36. **Eli Lilly B9U-MC-AZBJ**
Loracarbef vs. Amoxicillin in Acute Bronchitis
CRO/Sponsor: Pharmaco
Completed: July 1991

35. **Abbott M90-483**
A Multicenter, Double-blind, Randomized, Comparative Study of the Efficacy and Safety of Temafloxacin 600 mg BID and Ceclor 500 mg Q8h in the Treatment of Patients with Bacterial Infection of the Lower Respiratory Tract.
CRO/Sponsor: Abbott ~ Research Triangle Institute
Address: Abbot Park, IL
Completed: July 1991

34. **E.P.C.C.R. #4**
Study of Conditioning Effect during Allergen Immunotherapy on the Immune Response
CRO/Sponsor: 3M Diagnostics
Completed: December 1990

33. **E.P.C.C.R. #3**
A double blind placebo controlled evaluation of Intravenous Immunoglobulin in the therapy of chronic fatigue syndrome
CRO/Sponsor: Supported in part by Cutter
Completed: December 1990

32. **E.P.C.C.R. #2**
A pilot study evaluating intravenous immunoglobulin as a basis for the therapy of male infertility caused by antisperm antibodies
CRO/Sponsor: El Paso Institute for Medical Research and Development ~ Sandoz Pharmaceuticals
Address: El Paso, TX
Completed: June 1991

31. **E.P.C.C.R. #1**
The effects of suggestion on the secondary immune response.
CRO/Sponsor: El Paso Institute for Medical Research and Development
Address: El Paso, TX
Completed: November 1989

30. **Pfizer 6C475-C0602**
The efficacy and safety of oxymethozaline HCL 0.025% zinc sulfate 0.25% vs oxymetizaline HCL vs zinc sulfate 0.25% vs placebo vehicle in subjects with allergic conjunctivitis.
CRO/Sponsor: Pfizer, Inc. ~ SDRA
Address: Groton, CT ~ San Diego, CA

Completed: August 1990

29. **Merrel Dow 9918-3-C-162**
    A double-blind, randomized, placebo controlled parallel study comparing safety and Efficacy of Terfenadine 120 mg qid to hydroxyzine 25 mg qid administered for 12 weeks In the treatment of chronic idiopathic urticaria.
    CRO/Sponsor: Merrel Dow
    Address: Cincinnati, OH
    Completed: June 1992

28. **Rorer WHR-5029-503**
    A comparison of once daily Nasacort (Triamcinolone Acetonide) and twice daily Nasalide (Flunisolide) in patients with perennial allergic rhinitis.
    CRO/Sponsor: Rorer Central Research
    Address: Horsham, PA
    Completed: September 1990

27. **Wallace 251**
    A double-blind, placebo controlled, randomized, parallel group study of the safety and efficacy of azelastine and albuterol sulfate (Proventil Repetabs) in subjects with chronic asthma.
    CRO/Sponsor: Wallace Laboratories
    Address: Cranbury, New Jersey
    Completed: June 1991

26. **Rorer WHR-5029-118**
    A randomized, double-blind, placebo controlled double dummy, clinical study comparing the efficacy of Intranasal Triamcinolone Acetonide spray (Nasacort) and Bioequivalent doses of Intramuscular Triamcinolone Acetonide (Kenalog 40) in patients with seasonal rhinitis.
    CRO/Sponsor: Rorer Central Research
    Address: Horsham, PA
    Completed: June 1990

25. **Eli Lilly B9U-MC-AZAK**
    LY163892 vs. Augmentin in Pneumonia.
    Completed: October 1990

24. **Eli Lilly B9U-MC-AZAE**
    LY163892 vs. Augmentin in Bronchitis.
    Completed: October 1990

23. **Pzifer 066-113**
    Azithromycin in the Treatment of Acute Sinusitis. A Multicenter 3rd Party Blinded Trial Exploring Amoxicillin as a Comparative Agent.
    CRO/Sponsor: Pfizer
    Address: Groton, CT
    Completed: April 1990

22. **Pzifer 066-110**
    Azithromycin in the Treatment of Skin and Skin Structure Infections. A Multicenter 3rd Party Blinded Trial Exploring Keflex as a Comparative Agent.
    Address: Groton, CT
    Completed: April 1990

21. **3M-4**
    A Comparison of a Multiple Allergen Well to an Individual Allergen Miniscreen to Predict IgE Airborne Allergy.
    CRO/Sponsor: 3M Diagnostics Systems
    Address: Santa Clara, Ca.
    Completed: 1989

20. **Bristol Meyers CN1O2-003-006**
    Long Term Safety of Transnasal Butorphanol in Patients with Chronic Pain of Nonmalignant Origin.
    CRO/Sponsor: Bristol Meyers
    Completed: December 1990

19. **Rorer WHR-5029-116**
    A Double Blind Placebo Controlled Parallel Group Multiple Dose Study of WHR-5029 on Hypothalamic Pituitary Adrenal Axis Function.
    CRO/Sponsor: Rorer
    Address: Ft. Washington, PA
    Completed: February 1990

18. **Immunetech ASM-1-05-988**
    Safety and Tolerance and Efficacy Study of Inhaled Pentagetide in Blocking Allergen Bronchial Challenge.
    CRO/Sponsor: Immunetech
    Address: La Jolla, CA
    Completed: 1989

17. **Study No. 066-108**
    Azithromycin in the Treatment of Streptococcal Pharyngitis in Outpatients. A Multi-Center Third Party Blinded Trial Employing Penicillin V (V-Cillin K) as a Comparative Agent.
    CRO/Sponsor: Pfizer Labs
    Address: Groton, CT
    Completed: March 1990

16. **Study No. M88-202**
    A Multi-Center, Double-Blind, Randomized, Comparative Study of the Efficacy and Safety of Temofloxacin 600 mg BID and Ampicillin 500 mg QID in the Treatment of Lower Respiratory Tract Bacterial Infections.
    CRO/Sponsor: Abbott Labs
    Address: Abbott Park, IL
    Completed: 1989

15. **Study No. S87-057-13**
    Open-Label, Multi-Investigator Clinical Evaluation of Uni-Dur, a Twenty-Four Hour Theophylline Sustained Release Tablet.
    CRO/Sponsor: Schering Corporation
    Address: Kenilworth, N.J.
    Completed: 1988

14. **Study No. 174**
    Evaluation of the Steroid Sparing Effect of Azelastine in Patients Who Use Inhaled Steroids for Management of Bronchial Asthma.
    CRO/Sponsor: Wallace Laboratories
    Address: Cranbury, N.J.
    Completed: 1989

13. **Study No. 198**
    Placebo Controlled Comparison of the Effectiveness and Safety of Azelastine and Controlled Release Theophylline in the Management of Theophylline Dependent Asthmatics.
    CRO/Sponsor: Wallace Laboratories
    Address: Cranbury, N.J.
    Completed: 1989

12. **3M-3**
    Correlation between Fast and Prick Puncture Skin Testing.
    CRO/Sponsor: 3M Diagnostics Systems
    Address: Santa Clara, Ca.
    Completed: 1988

11. **Study No. 87-6**
    A Double-Blind Multi-Center Group Comparative Study of the Efficacy and Safety of Intel 5mg. Inhaler (Cromolyn Sodium) Vs. Placebo in the Management of Patients with Asthma.
    CRO/Sponsor: Fisons Corporation
    Address: Bedford, Mass.
    Completed: 1988

10. **Zaditen Study No. 32**

Theophylline Sparing Role of Zaditen in the Prophylaxis of Predominantly Moderate Extrinsic Asthma.
CRO/Sponsor: Sandoz Research Institute
Address: East Hanover, N.J.
Completed: 1989

9. **Study No. 85-36**
   A Double-Blind Multicenter Group Comparative Study of the Efficacy and Safety Of Tilade (Nedocromil Sodium) and the Intal Inhaler (Cromolyn Sodium) Vs. Placebo In the Management of Adults with Reversible Airways Obstruction.
   CRO/Sponsor: Fisons Corporation
   Address: Bedford, Mass.
   Completed: 1986

8. **Zaditen Study No. 24**
   A Comparison of Zaditen with Hi and Combination of H1 and H2 Antihistamine in the Inhibition of Dermographia.
   CRO/Sponsor: Sandoz Research Institute
   Address: East Hanover, NJ.
   Completed: 1987

7. **Study No. SAL-312**
   Efficacy and Safety of Ventolin Rotocaps (400 mcg.) in Children Ages 4 Through 11 Years.
   CRO/Sponsor: Glaxo, Inc.
   Address: Research Triangle Park, N.C.
   Completed: 1987

6. **Study No. SAL 303/313**
   A double-blind parallel group Multicenter study comparing the efficacy and safety of Albuterol Rotacaps (200mg) vs. Albuterol Aerosol (l8Omcg) administered four times per day in children ages 4 through 11 years with chronic reversible obstructive airway disease.
   CRO/Sponsor: Glaxo, Inc.
   Address: Research Triangle Park, N.C.
   Completed: 1987

5. **Quidel Inc.**
   Testing and comparison of dipstick method for Total IgE
   CRO/Sponsor: Quidel
   Address: San Diego, CA
   Completed: 1988

4. **Quidel Inc.**
   Comparison of Quidel method with Allergen Skin Testing.
   CRO/Sponsor: Quidel
   Address: San Diego, CA
   Completed: 1987

3. **Mast Immunosystems**
   Correlation of Mast Results to Prick Puncture Skin Testing.
   Address: Mast Immunosystems
   Completed: 1987

2. **Study 3M-2**
   A Regional Individual Allergen Based Miniscreen to Predict IgE Mediated Airborne Allergy
   CRO/Sponsor: 3M Diagnostics Systems
   Address: Santa Clara, CA
   Completed: 1987

1. **Study 3M-1**
   A comparison of the lot-to-lot variability of standardized and nonstandardized allergen extracts.
   CRO/Sponsor: 3M Diagnostics Systems
   Address: Santa Clara, CA
   Completed: 1988

Last Updated on 04/28/2014